Sanofi's Beyfortus Boosts Sales Amid Merck Competition and Expanded RSV Vaccine Production
Sanofi's Beyfortus has experienced significant sales growth, fortifying its market position amid competition from Merck's RSV antibody, clesrovimab. In the third quarter, Beyfortus achieved sales of €645 million, marking a 382% increase from the previous year, contributing to Sanofi's overall 15.7% sales growth[1][2]. This growth is supported by an expansion in production capacity by Sanofi and its partner AstraZeneca, to address earlier supply shortages driven by unexpected demand[2]. Despite Merck's imminent market entry, Sanofi remains optimistic, bolstered by Beyfortus's past efficacy and robust sales trajectory[1].
References
Explore Further
How is Sanofi planning to sustain Beyfortus's sales growth amid Merck's upcoming market entry with clesrovimab?
What strategies are Sanofi and AstraZeneca implementing to manage the increased demand and production of Beyfortus?
How significant is the impact of early flu vaccine orders on Sanofi's overall vaccine division sales growth?
What are the potential implications of Sanofi's negotiations to divest its consumer health business for its vaccine production capabilities?
How does the efficacy of Beyfortus compare to Merck's clesrovimab in terms of reducing RSV-related infections and hospitalizations?